Mallinckrodt to Present at J.P. Morgan Healthcare Conference January 12
December 22 2014 - 05:00PM
Business Wire
Mallinckrodt plc (NYSE: MNK), a global specialty
biopharmaceutical company, will present at the 33rd Annual J.P.
Morgan Healthcare Conference at the Westin St. Francis on Union
Square in San Francisco on Monday, January 12, 2015. Mark
Trudeau, President and Chief Executive Officer of Mallinckrodt,
will represent the company in a session scheduled to begin at 3
p.m. Pacific/6 p.m. Eastern.
Individuals who cannot attend the meeting in person can find
webcast information on Mallinckrodt’s Investor Relations website or
at: http://mallinckrodt.com/investor_relations. A replay will also
be available following the meeting.
ABOUT MALLINCKRODT
Mallinckrodt is a global specialty biopharmaceutical and medical
imaging business that develops, manufactures, markets and
distributes specialty pharmaceutical products and medical imaging
agents. Areas of focus include therapeutic drugs for autoimmune and
rare disease specialty areas like neurology, rheumatology,
nephrology and pulmonology along with analgesics and central
nervous system drugs for prescribing by office- and hospital-based
physicians. The company's core strengths include the acquisition
and management of highly regulated raw materials; deep regulatory
expertise; and specialized chemistry, formulation and manufacturing
capabilities. The company's Specialty Pharmaceuticals segment
includes branded and specialty generic drugs and active
pharmaceutical ingredients, and the Global Medical Imaging segment
includes contrast media and nuclear imaging agents. Mallinckrodt
has more than 5,500 employees worldwide and a commercial presence
in roughly 65 countries. The company's fiscal 2014 revenue totaled
$2.54 billion. To learn more about Mallinckrodt, visit
www.mallinckrodt.com.
MallinckrodtRhonda Sciarra, 314-654-8618Manager,
Communicationsrhonda.sciarra@mallinckrodt.comorMeredith Fischer,
314-654-3318Senior Vice President,
Communicationsmeredith.fischer@mallinckrodt.comorJohn Moten,
314-654-6650Vice President, Investor
Relationsjohn.moten@mallinckrodt.com
Mallinckrodt (NYSE:MNK)
Historical Stock Chart
From Feb 2024 to Mar 2024
Mallinckrodt (NYSE:MNK)
Historical Stock Chart
From Mar 2023 to Mar 2024